Clinical Trial Update: Study to Assess the Long Term Safety and Tolerability of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated the long-term safety and tolerability of ACT-541468 (daridorexant) in adults and elderly with insomnia disorder; the study is complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insomnia Disorder

Drugs mentioned

• ACT-541468 (Daridorexant) (daridorexant)

Snippet

Sponsor: Idorsia Pharmaceuticals Ltd. | Conditions: Insomnia Disorder | Phase 3 | Status: COMPLETED | Results posted: 2022-03-02